FSD Pharma says it’s still “very interested in synthetic cannabinoid platforms and will continue to pursue accretive opportunities in this area,” after Therapix Biosciences terminated the LOI to be purchased by FSD Pharma.
“While we are disappointed that Therapix Biosciences has given notice to terminate, we determined through the course of our negotiations and due diligence that a reset of some of the terms was in our shareholders’ best interests,” says FSD Pharma Executive Co-Chairman Raza Bokhari.
Date: December 24, 2018
Source: Seeking Alpha
